| CAS NO: | 15574-96-6 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 100mg | 电议 |
| 300mg | 电议 |
| 500mg | 电议 |
| Cas No. | 15574-96-6 |
| 别名 | 苯噻啶; Pizotyline; BC-105 |
| 化学名 | 4-(4,5-dihydrobenzo[1,2]cyclohepta[3,4-b]thiophen-10-ylidene)-1-methylpiperidine |
| Canonical SMILES | CN1CCC(=C2C3=C(CCC4=CC=CC=C42)SC=C3)CC1 |
| 分子式 | C19H21NS |
| 分子量 | 295.44 |
| 溶解度 | ≥ 14.77mg/mL in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Pizotifen (BC-105) is a potent 5-HT2 receptor antagonist, with a high affinity for 5-HT1C binding site. Pizotifen (BC-105) is a potent 5-HT2 receptor antagonist, with a high affinity for 5-HT1C binding site[1]. Pizotifen is an antidepresent 5-HT2A receptor antagonist and has the capacity to inhibit serotonin-enhanced ADP-induced platelet aggregation[2]. The weights of the fetuses are significantly reduced by all administered doses of Pipethiadene and Pizotifen (BC-105); the weights of the placentas are significantly reduced after 0.6 and 1.2 mg/kg Pipethiadene and only after the middle dose of Pizotifen. The means of the implantations, live, dead fetuses, resorptions and the occurrence of external, skeletal and visceral anomalies do not differ from the control group. The number of chromosome aberrations in the bone marrow cells of treated mice does not differ significantly from the negative control group. The micronucleus test reveals no elevation in the frequency of micronuclei as compared to the control group. After the two higher doses of both Pipethiadene and Pizotifen (BC-105) maleate, the mitotic indices are lower than in the control group[3]. References: |
m.cnreagent.com